Minerva Neurosciences logo

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
Management to host conference call WALTHAM, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
Management to host conference call WALTHAM, Mass. , April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020
Management to host conference call WALTHAM, Mass. , April 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021
Management to host conference call WALTHAM, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
Management to Host Conference Call BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Fiscal 2015 Fourth Quarter and Year End Financial Results and Business Updates on March 14, 2016
Management to Host Conference Call
View HTML
Toggle Summary Minerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017 View HTML
Toggle Summary Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
Management to host conference call WALTHAM, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019
Management to host conference call WALTHAM, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020
Management to host conference call WALTHAM, Mass. , March 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Displaying 161 - 170 of 194 results